EMBRACE II

Study design, population and eligibility

Treatment and comparator

External-beam RT: IMRT/VMAT 45 Gy in 25 fractions with daily image guidance, 5-mm PTV margins and risk-adapted elective nodal volumes. Involved nodes receive simultaneous integrated boost, generally 55–57 Gy.

Concurrent chemotherapy: Weekly cisplatin 40 mg/m², with at least five cycles intended.

Brachytherapy: MRI-guided adaptive brachytherapy with combined intracavitary/interstitial applicator techniques. Combined EBRT+BT planning aims include HR-CTV D90 90–95 Gy EQD2₁₀ (hard lower limit >85 Gy); GTVres D98 >95 Gy (hard >90 Gy).

Key OAR planning aims (EQD2₃): bladder D2cc <80 Gy; rectum <65 Gy; rectovaginal point <65 Gy; sigmoid and bowel D2cc <70 Gy. Hard prescribed-dose limits are generally bladder <90 Gy, rectum/rectovaginal point/sigmoid/bowel <75 Gy. Overall treatment time target ≤50 days.

Endpoints

EMBRACE II is a multi-endpoint benchmarking study, not a conventional trial with a single randomized primary endpoint. It evaluates local, nodal and systemic control; overall, disease-specific and disease-free survival; physician-assessed morbidity; patient-reported outcomes and quality of life; and dose–volume relationships for target and organs at risk.

Key efficacy and clinical outcomes

At the ESTRO 2025 presentation (data cut November 2024), three-year actuarial outcomes were: local control 93%, nodal control 91%, distant control 88%, overall disease control 80%, OS 87%, disease-specific survival 88% and DFS 78%.

For a high-risk subgroup (any N+, T3 or T4), three-year OS was 84%, DSS 86% and DFS 73%. In an INTERLACE-like subgroup without para-aortic nodal metastases, OS was 89%, DSS 91% and DFS 80%.

Crude grade 3–5 morbidity was 8.9% overall: urinary 2.8%, gastrointestinal 3.7%, vaginal 3.2%; fistula 1%. The presentation reported approximately 1% grade 4–5 morbidity in the specified organ categories.

Source-reported outcome visualization

Three-year actuarial disease-control and survival outcomes; crude G3–G5 morbidity is shown separately.

These are single-cohort benchmark outcomes, not randomized treatment effects. The morbidity figure is crude, not a three-year actuarial rate.

Absolute effect and NNT/NNH

There is no randomized control group, so comparative absolute risk reduction, NNT and NNH cannot be calculated. The most informative absolute outcomes are the three-year control/survival rates and the crude grade 3–5 morbidity rate. These must not be interpreted as causal superiority over EMBRACE I or other cohorts.

Trial-specific toxicity, grade 3–5 harms and treatment burden

Crude grade 3–5 morbidity was 8.9%; urinary 2.8%, GI 3.7%, vaginal 3.2%, and fistula approximately 1%. The study-group presentation reported grade 4–5 morbidity around 1% in the specified organ categories. These are cohort-level morbidity figures and should not be relabelled as randomized treatment-related adverse-event rates.

Treatment burden is substantial: 25 EBRT fractions, weekly cisplatin, repeated MRI-based brachytherapy applications, and stringent overall treatment time. The protocol seeks completion within 50 days.

Quality of life

Subgroups and applicability

Maturity, limitations and critical interpretation

Design: Prospective interventional cohort, not randomized. Outcomes cannot isolate the causal contribution of IMRT, nodal SIB, cisplatin, MRI-guided brachytherapy or treatment-time reduction individually.

Reporting: The overall results were presented at ESTRO 2025; a full peer-reviewed final outcomes publication was not identified in this audit. Study denominators vary slightly across public sources (1,449, 1,452 and 1,482), reflecting different report/analysis definitions. This page clearly uses the study-group presentation's 1,449 accrual count.

Generalizability: Accreditation, specialist brachytherapy expertise and protocol compliance may limit transferability to centres without comparable resources. QoL detail and full time-to-event confidence intervals were not available in the accessible summary.

Clinical interpretation: EMBRACE II is a major prospective benchmark for modern definitive cervical chemoradiotherapy: risk-adapted IMRT/VMAT, nodal boost, weekly cisplatin and MRI-guided intracavitary/interstitial brachytherapy produced excellent three-year local control and survival with lower reported severe morbidity than historical benchmarks. It supports protocolized high-quality delivery, but it is not a randomized comparison proving that any single component improves outcomes.

Primary sources, protocol and follow-up reports

1. EMBRACE II overall results, EMBRACE Collaborative Group / ESTRO 2025
2. EMBRACE II protocol (full PDF)
3. EMBRACE II study design and hypotheses, Radiotherapy and Oncology 2018
4. EBRT technique and planning evolution, IJROBP 2019 (PMID 30904706)
5. GEC-ESTRO completed clinical studies catalogue

Numbers not reported in the accessible primary source are not imputed. Median survival differences are never converted into NNT.